To the full analysis
Buyback calculator for GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals Stock: Key Metrics
GLAXO.NSGlaxoSmithKline Pharmaceuticals had an operating margin of 33% and a return on invested capital (ROIC) of 39.1% in fiscal 2026.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 22 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2007 | 95.9% | 29.7% | 34.8% |
| 2008 | 99.2% | 33.0% | 34.0% |
| 2009 | 102.7% | 33.5% | 34.9% |
| 2010 | 103.1% | 34.5% | 26.6% |
| 2011 | 103.9% | 35.2% | 26.1% |
| 2012 | 92.4% | 32.8% | 17.8% |
| 2013 | 86.4% | 30.1% | 21.2% |
| 2014 | 72.2% | 20.3% | 18.9% |
| 2015 | 53.5% | 33.6% | 14.4% |
| 2016 | 67.7% | 17.2% | 14.0% |
| 2017 | 62.6% | 13.5% | 11.6% |
| 2018 | 69.7% | 17.0% | 12.5% |
| 2019 | 71.3% | 18.0% | 14.4% |
| 2020 | 71.3% | 15.0% | 2.9% |
| 2021 | 53.8% | 17.9% | 12.4% |
| 2022 | 55.6% | 21.4% | no data |
| 2023 | 57.9% | 23.2% | 18.9% |
| 2024 | 58.7% | 24.4% | 17.1% |
| 2025 | 60.5% | 29.9% | 24.9% |
| 2026 | 43.6% | 33.0% | 27.1% |
Returns on Capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2007 | 45.7% | 26.3% | 30.8% |
| 2008 | 39.7% | 29.2% | 26.9% |
| 2009 | 37.5% | 40.9% | 25.5% |
| 2010 | 28.4% | 128.5% | 20.3% |
| 2011 | 28.7% | 26.7% | 19.9% |
| 2012 | 22.1% | 28.6% | 14.0% |
| 2013 | 28.0% | 25.6% | 18.2% |
| 2014 | 24.2% | 15.7% | 15.4% |
| 2015 | 15.6% | 22.5% | 11.8% |
| 2016 | 22.2% | 69.2% | 12.3% |
| 2017 | 16.8% | 35.1% | 11.2% |
| 2018 | 17.0% | 32.8% | 8.9% |
| 2019 | 20.8% | 40.8% | 11.4% |
| 2020 | 5.1% | 26.7% | 3.0% |
| 2021 | 24.2% | 56.1% | 11.5% |
| 2022 | no data | 14.7% | no data |
| 2023 | 35.1% | 21.6% | 18.4% |
| 2024 | 33.2% | 29.8% | 16.6% |
| 2025 | 47.5% | 38.7% | 22.6% |
| 2026 | 45.7% | 39.1% | 24.0% |
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Strong since 7 Nov 2026; valuation signal Overvalued since 22 Nov 2026
- Price: closing price of 20 Nov 2026
- Amounts in US dollars at the ECB reference rate of 20 Nov 2026 ($1 = ₹92.6752)
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2026. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
